NCT04281576

Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Completed NA Last updated 14 November 2024

What this trial tests

NA trial testing NovoTTF-100L(P) in Gastric Cancer in 28 participants. Completed in 7 June 2024.

Timeline

19 December 2019

Primary endpoint
7 June 2024

7 June 2024

Quick facts

Lead sponsor	NovoCure Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	19 December 2019
Primary completion	7 June 2024
Estimated completion	7 June 2024
Sites	1 location across Hong Kong

Drugs / interventions tested

• NovoTTF-100L(P)
• Oxaliplatin (Oxaliplatin) — full drug profile →
• Capecitabine (capecitabine) — full drug profile →
• Trastuzumab (trastuzumab) — full drug profile →

Conditions studied

• Gastric Cancer — all drugs for Gastric Cancer →
• GastroEsophageal Cancer — all drugs for GastroEsophageal Cancer →

Sponsor

NovoCure Ltd.

Who can join

18 and older, any sex, with Gastric Cancer or GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic Gastroesophageal Junction (GEJ) or Gastric (GC) Adenocarcinoma who were previously untreated with systemic therapy. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Tumour treating fields therapy for glioblastoma: current advances and future directions.
   Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, et al · · 2021 · cited 203× · PMID 33144698 · DOI 10.1038/s41416-020-01136-5
2. Tumor Treating Fields: At the Crossroads Between Physics and Biology for Cancer Treatment.
   Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, et al · · 2020 · cited 29× · PMID 33215030 · DOI 10.3389/fonc.2020.575992
3. <i>In Vivo</i> Safety of Tumor Treating Fields (TTFields) Applied to the Torso.
   Blatt R, Davidi S, Munster M, Shteingauz A, et al · · 2021 · cited 23× · PMID 34249709 · DOI 10.3389/fonc.2021.670809
4. Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions.
   Pal K, Sheth RA. · · 2022 · cited 11× · PMID 36612192 · DOI 10.3390/cancers15010196
5. Tumor treating fields: An emerging treatment modality for thoracic and abdominal cavity cancers.
   Jones TH, Song JW, Abushahin L. · · 2022 · cited 10× · PMID 34847422 · DOI 10.1016/j.tranon.2021.101296
6. Ion channels as molecular targets of glioblastoma electrotherapy.
   Abed T, Ganser K, Eckert F, Stransky N, et al · · 2023 · cited 6× · PMID 37006466 · DOI 10.3389/fncel.2023.1133984
7. Advancement in tumor treating fields of mechanism, clinical applications, and future directions.
   Zang M, Zhu S, Niu Q. · · 2025 · PMID 40495024 · DOI 10.1007/s12672-025-02861-0
8. Tumor-Treating Fields Alter Nanomechanical Properties of Pancreatic Ductal Adenocarcinoma Cells Co-Cultured with Extracellular Matrix.
   Kulkarni T, Banik S, Mukhopadhyay D, Babiker H, et al · · 2025 · PMID 40422825 · DOI 10.3390/jfb16050160